Introduction <p>Pre- and postprocedure skin care is crucial for patients undergoing energy-based device (EBD) treatments. A serum containing a proprietary blend of peptides to support extracellular matrix remodeling (TriHex Technology^®) was developed to aid skin preparation and recovery following aesthetic procedures. This analysis evaluated the skin recovery effects and safety of this serum in Asian subjects following fractional CO₂ laser (FCL) and radiofrequency microneedling (RFMN).</p> Methods <p>Two prospective, randomized, evaluator-blind, split-face studies were conducted. In the FCL study (<i>n</i> = 26), subjects applied a reference moisturizer on the entire face and the serum on an assigned hemi-face for 2&#xa0;weeks preprocedure. Postprocedure, the serum and moisturizer were applied to opposite hemi-faces for 3 days, followed by the preprocedure regimen until day 14. In the RFMN study (<i>n</i> = 25), serum and moisturizer were applied to opposite hemi-faces immediately postprocedure for 3 days, followed by serum on the assigned hemi-face and moisturizer on the entire face until day 14. Blinded clinical evaluations, self-assessments, and skin measurements were performed on days 0, 1, 3, 7, and 14.</p> Results <p>All 26 subjects (18 female, 8 male) completed the FCL study and 25 (24 female, 1 male) completed the RFMN study. Overall, the serum-treated side showed superior or comparable recovery versus control across multiple parameters. The primary endpoint of investigator-assessed erythema showed significant within-side improvement on both sides in both studies, while between-side differences did not reach statistical significance. Among secondary endpoints, the serum-treated side showed significantly greater recovery that withstood multiplicity correction for transepidermal water loss (TEWL) at day 3, and edema, VISIA redness, and tactile roughness at day 14 in the FCL study, while crusting at day 3 showed numerical improvement. In the RFMN study, the serum-treated side showed significantly greater edema reduction at day 7 that withstood correction; numerical improvements were observed for pain and heat sensation at day 1 and for erythema and crusting at day 7. On day 14, significantly more subjects reported better recovery on the serum-treated side (FCL, 81.8%; RFMN, 100%; <i>p</i> &lt; 0.05). Safety was favorable with few mild adverse events.</p> Conclusions <p>In these two exploratory studies, the topical serum containing TriHex Technology^® demonstrated superior or comparable recovery to a basic moisturizer across multiple parameters following FCL and RFMN in Asian subjects, with the most pronounced benefits in the early postprocedure period. These findings suggest that the serum may be a useful periprocedural adjunct, although further controlled studies are warranted.</p> Trial registration <p>Chictr.org.cn identifiers: ChiCTR2400089516 and ChiCTR2400089424.</p>